David A. Siegel Viridian Therapeutics, Inc.\De Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Two Sigma Advisers, LP holds 335,569 shares of VRDN stock, worth $5.23 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
335,569
Previous 444,800
24.56%
Holding current value
$5.23 Million
Previous $10.1 Million
36.44%
% of portfolio
0.02%
Previous 0.02%
Shares
7 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$74.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$71.6 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$70.5 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$60.5 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$54.9 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $621M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...